Comparative safety of long-acting inhaled bronchodilators: A cohort study using the UK THIN primary care database

Drug Safety

Volumn 30, Issue 12, 2007, Pages 1151-1160

  Jara, Michele ^a   Lanes, Stephan F ^a   Wentworth III, Charles ^b   May, Corey ^b   Kesten, Steven ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b Analytic Consulting Solutions Inc   (United States)

Author keywords

Adverse drug reactions incidence; Beta adrenergic receptor agonists, adverse reactions; Bronchodilators, adverse reactions; Bronchodilators, therapeutic use; Cholinergic receptor agonists, adverse reactions

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID DERIVATIVE; FORMOTEROL; SALMETEROL; TIOTROPIUM BROMIDE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ASTHMA; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DATA BASE; DRUG APPROVAL; DRUG SAFETY; FEMALE; GENERAL PRACTITIONER; HAZARD RATIO; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PNEUMONIA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; SCORING SYSTEM; TACHYCARDIA; TREATMENT INDICATION;

EID: 36448935172     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730120-00007     Document Type: Article

References (35)

1. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-76
2. Sin DD, Man P. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? Circulation 2003; 107 (11): 1514-9
3. Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999; 64: 457-64
4. Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127 (3): 809-17
5. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143 (5): 317-26
6. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 hours with once-daily tiotropium in patients with COPD. Chest 2005; 128 (3): 1168-78
7. Kesten S, Jara M, Wentworth C, et al. Pooled clinical trial analysis of tiotropium safety. Chest 2006; 130: 1695-703
8. Morganroth J, Golisch W, Kesten S. Lack of cardiac safety signals in COPD patients receiving tiotropium as defined by electrocardiographic monitoring in placebo controlled trials. J COPD 2004; 1: 181-90
9. Covelli H, Bhattacharya S, Cassino C, et al. Absence of electrocardiographic findings and improved function with daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy 2005; 25: 1708-18
10. Currie GP, Lipworth BJ. ABC of chronic obstructive pulmonary disease: pharmacologic management-inhaled treatment. BMJ 2006; 332: 1439-41
11. Nelson HS, Weiss ST, Bleecker ER, et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15-26
12. GlaxoSmithKline. Serevent® product information, RL-2033. Research Triangle Park (NC): GlaxoSmithKline, 2003 Aug
13. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004; 12: 171-7
14. Lewis JD, Schinnar R, Bilder WB, et al. Validation studies of The Health Improvement Network (THIN) database for Pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007; 16: 393-401
15. Oracle9i database. Redwood Shores (CA): Oracle Corporation, 2000
16. STATA 7.0. College Station (TX): StataCorp, 2002
17. CDC. Chronic obstructive pulmonary disease surveillance: United States, 1971-2000 [online]. Available from URL: http://www.cdc.gov/mmwr/preview/ mmwrhtml/ss5106a1.htm [Accessed 2006 May 12]
18. CDC. Surveillance for asthma: United States, 1980-1999 [online]. Available from URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/ss5101a1.htm [Accessed 2006 May 12]
19. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med 2002; 137: 693-6
20. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999, 333
21. Robins JM, Mark SD, Newey WK. Estimating exposure effects by modelling the expectations of exposure conditional on confounders. Biometrics 1992; 48: 479-95
22. Rubin DB. On principles for modeling propensity scores in medical research. Pharmacoepidemiol Drug Saf 2005; 13: 855-7
23. Rothman KJ, Greenland S. Approaches to statistical analysis. In: Rothman KJ, Greenland S, editors. Modern epidemiology. 2nd ed. Philadelphia (PA): Lippincott-Raven Publishers, 1998: 183-99
24. SensTool.xls from the Boston University School of Public Health [online]. Available from URL: http://www.bu.edu/dbin/sph/departments/epidemiology/ epidemiologic_methods_research.php [Accessed 2006 Feb 8]
25. Fox MP, Lash TL, Greenland S. A method to automate probabilistic sensitivity analyses of misclassified binary variables. Int J Epidemiol 2005; 34: 1370-6
26. Garcia Rodriguez LA, Pérez-Gutthann S, Jick S. The UK General Practice Research Database. In: Strom BL, editor. Pharmacoepidemiology. 3rd ed. New York: John Wiley & Sons, Ltd, 2000: 375-85
27. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada: cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16: 63-70
28. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55
29. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404
30. Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med 2000; 93: 457-62
31. Costello R. Pharmacology. In: Calverly PMA, MacNee W, Pride NB, et al., editors. Chronic obstructive pulmonary disease. 2nd ed. London: Arnold, 2003: 341-56
32. Sovani MP, Whale CI, Tattersfield AE. A benefit-risk assessment of inhaled long-acting β2-agonists in the management of obstructive pulmonary disease. Drug Saf 2004; 27 (10): 689-715
33. Ferguson GT, Funck-Brentano C, Fisher T, et al. Cardiovascular safety of salmeterol in COPD. Chest 2003; 123: 1817-24
34. Cepeda MS, Boston R, Farrar JT, et al. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 2003; 158: 280-7
35. Cazzola M, Imperatore F, Salzillo A, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998; 114: 411-5